report adjust ep consensu
expect higher estim strong organ growth
lower-than-anticip adjust tax rate drove upsid rel
adjust ep forecast
syk revenu increas year-over-year million
consensu expect million forecast
million exclud acquisit chang foreign currenc exchang
rate syk sale improv organ
forecast led strength medsurg equip organ versu
forecast particularli instrument busi constant
currenc roughli organ exclud invuiti safeair ag
acquisit versu forecast compani orthoped divis also
modestli exceed revenu forecast led favor mako unit sale
slightli better hip knee implant organ growth model
versu forecast
syk adjust oper margin increas bp year-over-year
slightli forecast compani
adjust gross margin softer expect roughli bp
year-over-year primarili reflect product mix issu given
strength medsurg equip sale corpor averag
gross margin similar oper margin rel overal busi
note syk price growth neg year-over-year improv
recent quarter acquisit bp dilut compani
adjust oper margin year-over-year basi
follow strong rais organ growth guidanc
impli organ growth
notabl compani spoke posit order backlog mako
medsurg equip product enter benefit
back half year recent launch high definit
camera system endoscopi compani also increas adjust
ep guidanc addit higher organ
growth assumpt continu expect bp adjust oper
margin expans bp expans move
past acquisit integr continu realiz strong expens
save transform growth initi
total debt total asset
deliv anoth quarter better-than-expect organ growth
upsid consensu adjust ep estim remain posit
compani long-term outlook rais adjust
ep estim respect
maintain buy rate increas price target
import pleas read disclosur disclaim page report
report adjust ep consensu expect higher
estim strong organ growth lower-than-anticip adjust tax rate drove upsid
rel adjust ep forecast
stryker adjust incom statement analysisnorthcoast research million except percentag per share sg interest incom incom margin incom trauma sustain compani report northcoast research estim factset syk revenu increas year-over-year million consensu expect
million forecast million exclud acquisit chang foreign currenc exchang
rate syk sale improv organ forecast
divis standpoint strong result syk medsurg equip divis drove upsid
organ growth forecast compani orthoped product sale also modestli higher
medsurg equip achiev organ growth forecast
repres compani best perform divis sinc quarter result strong
across divis four segment led high-teen organ growth instrument adjust invuiti
safeair ag acquisit mid-teen organ growth sustain solut high-single-digit organ
growth endoscopi medic favor domest medic perform weigh sale declin
intern rel estim magnitud strength syk instrument busi
biggest upsid surpris quarter compani continu benefit split instrument sale forc
surgic technolog orthoped instrument meaning increas total number sale
repres combin team product standpoint call power surgic instrument
neptun wast manag system key contributor except strong instrument organ
growth quarter
stryker corporationtot compani organ growth analysi two fewer sale day year-over-year one extra sale day year-over-year one fewer sale day year-over-year compani report corpor organ growth analysiscategorynorthcoastreportedtot compani organ orthoped medsurg equip neurotechnolog spine compani report northcoast research estim
orthoped product syk sale increas organ estim
quarter strength mako capit sale versu drove high-teen organ growth orthoped
product versu estim compani combin hip knee implant organ growth slightli
exceed forecast organ versu estim strength area off-set modest
growth anticip syk trauma extrem organ growth year-over-year
compani held back delay launch alpha nail system roll
knee implant achiev organ growth similar forecast
quarter compani knee implant organ growth year-over-year benefit increas
demand cementless triathlon tritanium knee system use compani domest
knee implant case addit mako system sale competit account increas surgeon train
mako total knee implant applic total case perform syk mako total
knee
hip implant achiev organ growth forecast rel
similar perform domest intern market similar recent quarter compani hip implant
busi continu led print trident ii acetabular system increas util mako hip
procedur overal encourag see acceler anticip hip implant busi
despit focu sale forc key differenti knee mako total knee applic cementless knee
neurotechnolog spine product achiev organ growth modestli
forecast neurotechnolog organ growth remain modestli recent year spine organ
growth also modestli expect said think new product includ broader array
aspir product ischem stroke treatment drive neurotechnolog organ growth back
double-digit rang continu expect mid-single-digit pro forma organ growth
spine busi move past acquisit integr effort slow compani spine
perform expect
stryker corporationworldwid hip implant organ growth analysi two fewer sale day year-over-year one extra sale day year-over-year one fewer sale day year-over-yearsourc compani report syk adjust oper margin increas bp year-over-year slightli
forecast compani adjust gross margin softer expect roughli bp
year-over-year primarili reflect product mix issu given strength medsurg equip
sale corpor averag gross margin similar oper margin rel overal
busi note syk price growth neg year-over-year improv recent quarter
acquisit bp dilut compani adjust oper margin year-over-year basi
follow strong rais organ growth guidanc impli
organ growth notabl compani spoke posit order backlog mako
medsurg equip product enter benefit back half year recent
launch high definit camera system endoscopi compani also increas
adjust ep guidanc addit higher organ growth assumpt
continu expect bp adjust oper margin expans bp expans
stryker corporationneurotechnolog spine organ growth analysi compani report two fewer sale day year-over-year one extra sale day year-over-year one fewer sale day corporationtot compani price growth year-over-year compani report move past acquisit integr continu realiz strong expens save
transform growth initi
overal deliv anoth quarter better-than-expect organ growth upsid consensu
adjust ep estim remain posit compani long-term outlook rais
adjust ep estim respect maintain buy
rate increas price target
stryker corporationannu incom statement analysi adjust northcoast research million except percentag per share gross gross sg oper oper net interest incom incom tax incom extra incom extra extra net net wghd com share ep ep growth ep growth start exclud acquistion-rel intang amort expens adjust ep compani report northcoast research estim disclosur
